Basic study on new treatment strategy targeting mevalonate pathway in prostate cancer

前列腺癌甲羟戊酸通路新治疗策略的基础研究

• 批准号: 20791102
• 负责人: NOMURA Masashi
• 金额: $ 1.58万
• 依托单位: Gunma University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Young Scientists (B)
• 财政年份: 2008
• 资助国家: 日本
• 起止时间: 2008 至 2009
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-20791102/
• 关键词: 前立腺癌; メバロン酸経路; スタチン; 脂質; ゾレドロン酸

In this study, the therapeutic potential of statin and zoledoronic acid, mevalotate pathway targeting agents, was studied. Both agents inhibited prostate cancer cell proliferations, especially, statins specifically inhibited proliferation of PC-3, androgen-independent cells. Prostate cancer cells expressed LDL receptor. LNCAP cells had abilities to regulate expression of LDL receptor in response to exogeneous or endogenouse lipid levels. In contrast, PC-3 lacked this ability and statin exerts its antiproliferative effect in PC-3 cells. These results suggested that mevalonate targeting agents, such as statin and zoledoronic acid, have potentials to use for prostate cancer.

在这项研究中，研究了他汀类药物和唑多德丙酸的治疗潜力，甲氯替酸途径的靶向剂。两种药物都抑制了前列腺癌细胞增殖，尤其是他汀类药物特别抑制了PC-3，雄激素非依赖性细胞的增殖。前列腺癌细胞表达LDL受体。 LNCAP细胞有能力调节响应于外源或内源脂质水平的LDL受体的表达。相反，PC-3缺乏这种能力，他汀类药物在PC-3细胞中施加了抗增殖作用。这些结果表明，甲他酸盐靶标（例如他汀类药物和唑类丙二酸）具有用于前列腺癌的潜力。